iECURE receives FDA Fast Track designation for neonatal onset Ornithine Transcarbamylase (OTC) deficiency treatment
iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, has received Fast Track designation from the U.S. Food …